慢性完全闭塞病变PCI治疗稳定型心绞痛的随机安慰剂对照试验:ORBITA-CTO研究
ORBITA-CTO是首个慢性完全闭塞病变(CTO)经皮冠状动脉介入治疗(PCI)的随机安慰剂对照试验,纳入50例单支血管CTO且无旁观病变的稳定型心绞痛患者。结果显示,与安慰剂手术相比,CTO PCI即刻且持续改善心绞痛症状评分(OR 4.38;95%CrI 1.57-12.69;Pr[Benefit]=0.996),并增加无心绞痛天数30.6天(95%CrI 11.1-50.7)。患者、工作人员及研究者盲法均得以维持。
要点
- CTO PCI较安慰剂显著改善心绞痛症状评分,得益于心绞痛发作次数减少。
- CTO PCI额外增加30.6天无 angina 天数,SAQ心绞痛频率等评分亦改善。
- 患者、工作人员及研究者盲法成功维持,支持结果可靠性。
核心结论
- 在有症状的单支血管CTO患者中,CTO PCI较安慰剂手术能改善心绞痛症状。
研究设计与样本
- ORBITA-CTO为多中心、随机、盲法试验,比较CTO PCI与安慰剂手术。
- 患者为单一血管CTO导致心绞痛且无旁观冠状动脉疾病,共50例随机分配至CTO PCI(n=25)或安慰剂(n=25)。
- 随机后停用抗心绞痛药物,按患者启动方案重新引入,6个月随访重复评估。
主要发现
- 与安慰剂相比,CTO PCI使心绞痛症状评分即刻且持续改善(OR 4.38;95%CrI 1.57-12.69;Pr[Benefit]=0.996)。
- 心绞痛发作次数明显减少(OR 4.38;95%CrI 1.55-11.78;Pr[Benefit]=0.997)。
- 额外增加30.6天无心绞痛天数(95%CrI 11.1-50.7;Pr[Benefit]>0.999)。
- 西雅图心绞痛问卷心绞痛频率改善(+10.7;95%CrI 1.4-20.2;Pr[Benefit]=0.988),躯体受限、生活质量、总结评分及加拿大心血管学会分级亦改善。
- 患者、工作人员及研究者的盲法均得以维持。
关键数值与推荐
- 主要疗效终点为心绞痛症状评分,为结合ORBITA应用程序每日症状负担、抗心绞痛药物使用及over-ride事件的序数 scale。
临床怎么用
- 对于症状性单支血管CTO且无旁观病变的患者,CTO PCI可作为改善心绞痛的治疗选择。
局限性
- 样本量较小(共50例),可能影响结果的普遍性。
- 随机至PCI组的一名患者因并发症在术中退出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous coronary intervention for coronary chronic total occlusion (CTO PCI) is offered for symptom and quality of life improvement, despite the absence of blinded randomized evidence. OBJECTIVES: The aim of this study was to assess the efficacy of CTO PCI in the first randomized, placebo-controlled trial of CTO PCI. METHODS: ORBITA-CTO is a multicenter, randomized, blinded trial comparing CTO PCI with a placebo procedure. Patients had angina attributable to a single-vessel CTO, without bystander coronary disease. Angina symptoms were recorded daily using the ORBITA app. After dual-injection coronary angiography, patients were randomized to either CTO PCI or placebo. Blinding was maintained using auditory isolation and deep conscious sedation. Antianginal medications were stopped at randomization and reintroduced on a patient-initiated protocol. At the 6-month follow-up, assessments were repeated. The primary efficacy outcome was the angina symptom score, an ordinal scale combining the daily symptom burden assessed by the ORBITA app, antianginal use, and over-ride events. Secondary outcomes were symptom and quality of life questionnaires and blinding fidelity. RESULTS: Between October 19, 2021 and October 21, 2025, 50 patients were randomly assigned to CTO PCI (n = 25) or placebo (n = 25). One patient randomized to PCI was withdrawn during the procedure because of a complication. All 50 patients were included in the primary analysis. Compared with placebo, CTO PCI resulted in an immediate and sustained improvement in the angina symptom score (OR: 4.38; 95% credible interval [CrI]: 1.57-12.69; probability of benefit [Pr{Benefit}] = 0.996), arising from a clear reduction in the number of episodes of angina (OR: 4.38; 95% CrI: 1.55-11.78; Pr[Benefit] = 0.997). This resulted in an additional 30.6 days free of angina (95% CrI: 11.1-50.7; Pr[Benefit] >0.999). Improvements were also observed with the Seattle Angina Questionnaire in angina frequency (+10.7; 95% CrI: 1.4-20.2; Pr[Benefit] = 0.988), physical limitation, quality of life, and summary score and Canadian Cardiovascular Society class. Blinding of patients, staff, and researchers was maintained. CONCLUSIONS: In patients with symptomatic single-vessel CTO, CTO PCI improves angina beyond placebo. (A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina [ORBITA-CTO]; NCT05142215).
引用
- Khan S, Sajjad U, Fawaz S, et al. Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: The ORBITA-CTO Trial. J Am Coll Cardiol. 2026. PMID: 41999379. doi:10.1016/j.jacc.2026.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。